As a Swiss pharmaceutical company headquartered in Zurich, we develop, manufacture and internationally market well-proven and innovative pharmaceuticals in novel drug delivery forms. Under our brand ‘Acino Switzerland’, we provide high-quality medicines to emerging markets with a strategic focus on the Middle East, Africa, Ukraine/CIS including Russia, and Latin America.
Acino is a leader in advanced drug delivery technologies specializing in modified release oral forms and oral dispersible forms, for which it also holds patents. As a partner of pharmaceutical companies worldwide, we also supply finished in-house developed products and provide customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics.
On November 30, 2016, Acino International AG and Acino Pharma AG (together “Acino”) closed the deal with Luye Pharma Group Ltd. and sold Acino’s transdermal patch and implant businesses. The divestment includes Acino’s transdermal manufacturing operations in Miesbach, Germany, distribution, and R&D capabilities.
Acino retains the marketing rights to certain transdermal patches in our strategic emerging markets.